IL310132B2 - Methods for treating and preventing Alzheimer's disease - Google Patents

Methods for treating and preventing Alzheimer's disease

Info

Publication number
IL310132B2
IL310132B2 IL310132A IL31013224A IL310132B2 IL 310132 B2 IL310132 B2 IL 310132B2 IL 310132 A IL310132 A IL 310132A IL 31013224 A IL31013224 A IL 31013224A IL 310132 B2 IL310132 B2 IL 310132B2
Authority
IL
Israel
Prior art keywords
alzheimer
disease
prevention
treatment
methods
Prior art date
Application number
IL310132A
Other languages
English (en)
Hebrew (he)
Other versions
IL310132B1 (en
IL310132A (en
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of IL310132A publication Critical patent/IL310132A/en
Publication of IL310132B1 publication Critical patent/IL310132B1/en
Publication of IL310132B2 publication Critical patent/IL310132B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
IL310132A 2018-07-24 2019-07-23 Methods for treating and preventing Alzheimer's disease IL310132B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862702659P 2018-07-24 2018-07-24
US201862749614P 2018-10-23 2018-10-23
US201962824162P 2019-03-26 2019-03-26
US201962846902P 2019-05-13 2019-05-13
US201962874684P 2019-07-16 2019-07-16
PCT/US2019/043067 WO2020023530A2 (en) 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease

Publications (3)

Publication Number Publication Date
IL310132A IL310132A (en) 2024-03-01
IL310132B1 IL310132B1 (en) 2025-11-01
IL310132B2 true IL310132B2 (en) 2026-03-01

Family

ID=67551415

Family Applications (3)

Application Number Title Priority Date Filing Date
IL310132A IL310132B2 (en) 2018-07-24 2019-07-23 Methods for treating and preventing Alzheimer's disease
IL280315A IL280315B2 (en) 2018-07-24 2019-07-23 Methods for treating and preventing Alzheimer's disease
IL323583A IL323583A (en) 2018-07-24 2025-09-25 Methods for treating and preventing Alzheimer's disease

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL280315A IL280315B2 (en) 2018-07-24 2019-07-23 Methods for treating and preventing Alzheimer's disease
IL323583A IL323583A (en) 2018-07-24 2025-09-25 Methods for treating and preventing Alzheimer's disease

Country Status (13)

Country Link
US (1) US20210324056A1 (https=)
EP (1) EP3826674A2 (https=)
JP (2) JP7541505B2 (https=)
KR (1) KR20210039402A (https=)
CN (2) CN118924896A (https=)
AU (1) AU2019309938B2 (https=)
BR (1) BR112021001272A2 (https=)
CA (1) CA3107370A1 (https=)
IL (3) IL310132B2 (https=)
MX (1) MX2021000778A (https=)
PH (1) PH12021500006A1 (https=)
TW (1) TW202019471A (https=)
WO (1) WO2020023530A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
KR20220156534A (ko) * 2020-03-20 2022-11-25 에자이 알앤드디 매니지먼트 가부시키가이샤 고농도 항-Aβ 프로토피브릴 항체 제형물 및 이의 사용 방법
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
WO2022035758A1 (en) * 2020-08-12 2022-02-17 The Cleveland Clinic Foundation Bace1 inhibitor treatment for suppressing cytokine storm
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
KR20240115910A (ko) * 2021-12-17 2024-07-26 에자이 알앤드디 매니지먼트 가부시키가이샤 항-아밀로이드 베타 원섬유 항체 및 항-타우 항체의 사용 방법
WO2023111618A1 (en) * 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
MX2024009492A (es) * 2022-02-02 2024-08-09 Eisai R&D Man Co Ltd Metodos de tratamiento mediante el uso del nivel de proteina tau fosforilada 181 (p-tau181).

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
AU2016208353B2 (en) * 2007-10-17 2017-07-20 Janssen Alzheimer Immunotherapy Immunotherapy regimes dependent on ApoE status
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
RU2476431C2 (ru) 2008-01-18 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Конденсированное производное аминодигидротиазина
PT2448968T (pt) 2009-06-29 2021-04-30 Bioarctic Ab ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL
JP2013521233A (ja) * 2010-02-25 2013-06-10 ヤンセン アルツハイマー イミュノセラピー Aβを標的とする免疫療法のPETモニタリング
CA2789963C (en) 2010-02-26 2019-09-03 Bioarctic Neuroscience Ab Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
US8426584B2 (en) 2011-01-21 2013-04-23 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
EP3166970B1 (en) * 2014-07-10 2021-03-10 BioArctic AB Improved a-beta protofibril binding antibodies
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
BR112018014762A2 (pt) * 2016-01-20 2018-12-26 Genentech Inc método de tratamento da doença de alzheimer (da) precoce
ES2939373T3 (es) * 2016-05-13 2023-04-21 Pasteur Institut Inhibición de los receptores de acetilcolina nicotínicos beta-2 para tratar la patología de la enfermedad de Alzheimer
TWI798751B (zh) * 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗-N3pGlu類澱粉β肽抗體及其用途
CN117244056A (zh) * 2016-10-27 2023-12-19 卫材研究发展管理有限公司 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物

Also Published As

Publication number Publication date
AU2019309938A1 (en) 2021-03-11
IL280315B2 (en) 2024-06-01
WO2020023530A3 (en) 2020-03-12
EP3826674A2 (en) 2021-06-02
IL280315A (en) 2021-03-25
WO2020023530A2 (en) 2020-01-30
AU2019309938B2 (en) 2026-04-02
CN118924896A (zh) 2024-11-12
PH12021500006A1 (en) 2021-09-13
CA3107370A1 (en) 2020-01-30
JP7541505B2 (ja) 2024-08-28
KR20210039402A (ko) 2021-04-09
BR112021001272A2 (pt) 2021-04-27
CN112805031A (zh) 2021-05-14
TW202019471A (zh) 2020-06-01
IL280315B1 (en) 2024-02-01
IL310132B1 (en) 2025-11-01
IL323583A (en) 2025-11-01
US20210324056A1 (en) 2021-10-21
IL310132A (en) 2024-03-01
JP2024112859A (ja) 2024-08-21
MX2021000778A (es) 2021-03-31
JP2021532126A (ja) 2021-11-25

Similar Documents

Publication Publication Date Title
IL310132B2 (en) Methods for treating and preventing Alzheimer's disease
IL277577A (en) Antibody-based methods for the detection and treatment of Alzheimer's disease
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
SG11202011296VA (en) Compositions and methods for the treatment of parkinson's disease
IL288894A (en) Methods for the assessment and treatment of Alzheimer's disease and their applications
IL272097A (en) Compounds for the prevention and treatment of medical disorders and their uses
IL269083A (en) Methods for preventing and treating heart disease
EP3773500A4 (en) COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE
ZA202000558B (en) Prevention and/or treatment of neurodegenerative disease
IL265911A (en) Epilimod preparations and methods of using them in the treatment of Alzheimer's disease
ZA202101489B (en) Compositions and methods for the treatment of parkinson's disease
PT3458045T (pt) Ebselen para uso no tratamento da doença de ménière
EP3398614A4 (en) AGENTS FOR PREVENTION AND / OR TREATMENT OF MORBUS ALZHEIMER
EP3610879A4 (en) COMPOSITION OF TREATMENT AND / OR PREVENTION OF ALZHEIMER'S DISEASE
PL3137097T3 (pl) Leczenie i profilaktyka choroby Alzheimera (AD)
PT3137094T (pt) Tratamento e prevenção da doença de alzheimer (da)
ZA201906964B (en) Prevention and/or treatment of inflammatory skin disease
IL268131A (en) A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of alzheimer's disease
EP3646872A4 (en) MEANS FOR PREVENTION AND / OR TREATMENT OF ALZHEIMER'S MORBUS
EP3634979A4 (en) COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S MORBUS
HUE037501T2 (hu) Alzheimer-kór (AD) kezelése és megelõzése
ZA202001588B (en) Method of treating alzheimer's disease
HK40052061A (en) Methods of treatment and prevention of alzheimer's disease
HK40074615A (en) Methods for evaluation and treatment of alzheimer's disease and applications thereof
GB201819758D0 (en) Medicine for the treatment of Alzheimer's disease